Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Change in Inventory (2022 - 2025)

Historic Change in Inventory for Atara Biotherapeutics (ATRA) over the last 4 years, with Q1 2025 value amounting to -$10.7 million.

  • Atara Biotherapeutics' Change in Inventory fell 26705.86% to -$10.7 million in Q1 2025 from the same period last year, while for Sep 2025 it was -$10.5 million, marking a year-over-year decrease of 24203.55%. This contributed to the annual value of $4.4 million for FY2024, which is 4539.41% down from last year.
  • According to the latest figures from Q1 2025, Atara Biotherapeutics' Change in Inventory is -$10.7 million, which was down 26705.86% from $160000.0 recorded in Q4 2024.
  • In the past 5 years, Atara Biotherapeutics' Change in Inventory registered a high of $6.4 million during Q1 2024, and its lowest value of -$10.7 million during Q1 2025.
  • Moreover, its 4-year median value for Change in Inventory was $2.1 million (2022), whereas its average is $348500.0.
  • Its Change in Inventory has fluctuated over the past 5 years, first soared by 9640.61% in 2023, then tumbled by 27551.18% in 2024.
  • Over the past 4 years, Atara Biotherapeutics' Change in Inventory (Quarter) stood at $1.6 million in 2022, then skyrocketed by 96.41% to $3.1 million in 2023, then tumbled by 94.86% to $160000.0 in 2024, then tumbled by 6759.38% to -$10.7 million in 2025.
  • Its Change in Inventory stands at -$10.7 million for Q1 2025, versus $160000.0 for Q4 2024 and -$4.8 million for Q3 2024.